Table 2 Summary of cardiac events.
CEs, subtype and timing | All pts (4190) N (%) | T arm (2097) N (%) | T + L arm (2093) N (%) |
|---|---|---|---|
Cardiac events | 363 (8.6) | 197 (9.3) | 166 (7.9) |
CE during anti-HER2 therapy | 270 (6.4) | 153 (7.2) | 117 (5.6) |
CE during follow-up phase | 93 (2.2) | 44 (2.1) | 49 (2.3) |
Asymptomatic CE | 265 (6.3) | 155 (7.4) | 110 (5.3) |
Symptomatic CE | 94 (2.2) | 40 (1.9) | 54 (2.6) |
Cardiac deaths | 4 (<0.1) | 2 (<0.1) | 2 (<0.1) |
Median time in months to develop a CE (range) | 6.6 (3.4–11.7) | 6.4 (3.6–11.7) | 7.1 (2.9–16.6) |
